Prot #1199.214: A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’(SSc-ILD)

Project: Research project

Project Details

StatusFinished
Effective start/end date2/11/1611/30/21

Funding

  • Boehringer Ingelheim Pharmaceuticals, Inc. (Prot #1199.214)